This article needs to be updated.(February 2026) |
| Company type | Aktieselskab |
|---|---|
| Industry | Pharmaceuticals, health care [1] |
| Founded | 1958 [1] |
| Headquarters | Copenhagen, Denmark [1] |
| Website | http://www.xellia.com |
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen [1] specialized in the production of anti-biotics, including Vancomycin [2] and Bacitracin. [3]
The company's US base of operations is in Buffalo Grove, Illinois, [4] [5] with additional facilities in Ohio, and North Carolina. [6] [7] In 2018, Xellia's sales in the United States accounted for 60% of its total revenue. [5]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are: [8]
Previously the company also produced:
| Ingredient | Produced |
|---|---|
| Neomycin | 1952-? |
| Tetracycline | 1961-? |
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market. [4] [19] [20] [21] [22]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war. [23]